| Treatment . | KC GEMM . | KCP GEMM . | PDAC model . | CT26 KRAS G12D (Quintana et al., 2020) . | CT26 KRAS G12C (Canon et al., 2019) . |
|---|---|---|---|---|---|
| CD3+ T cells | |||||
| SHP2-I | ↑ | NS | ↑ | ↑ | ND |
| G12C-I | ↑ | ↑ | ↑ | ND | ↑ |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| CD19+ cells | |||||
| SHP2-I | ↑ | ↑ | NS | ND | ND |
| G12C-I | ↑ | NS | ↑ | ND | ND |
| COMBO | ↑ | NS | ↑ | ND | ND |
| CD11b+ myeloid cells | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | NS | ↓ | ND | ND |
| CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | ↑ | ND |
| G12C-I | ↑ | NS | NS | ND | ↑ |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| Activated CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | NS | ↑ | ND |
| G12C-I | NS | NS | NS | ND | ND |
| COMBO | NS | ↑ | NS | ND | ND |
| Exhausted CD8+ T cells | |||||
| SHP2-I | NS | ↑ | ↑ | NS | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | NS | ↑ | ↑ | ND | ND |
| Effector CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | ND | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| CD4+ T cells | |||||
| SHP2-I | ↓ | ↓ | ↓ | ↑ | ND |
| G12C-I | NS | NS | NS | ND | ↑ |
| COMBO | NS | NS | ↓ | ND | ND |
| CTLA4+ CD4+ T cells | |||||
| SHP2-I | NS | ↓ | ↑ | ND | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | ↓ | NS | ↑ | ND | ND |
| FOXP3+ CD4+ T cells | |||||
| SHP2-I | NS | NS | ↓ | ND | ND |
| G12C-I | NS | NS | NS | ND | ND |
| COMBO | ↓ | NS | ↓ | ND | ND |
| CD8+/T reg cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | NS | ND |
| G12C-I | ↑ | ↑ | ↑ | ND | ND |
| COMBO | ↑ | NS | ↑ | ND | ND |
| m-MDSCs | |||||
| SHP2-I | ↑ | ↑ | ↓ | NS | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | ↑ | NS | ND | ND |
| g-MDSCs | |||||
| SHP2-I | ↑ | NS | NS | NS | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | NS | ↓ | ND | ND |
| F4/80 macrophages | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | ↑ | ↑ | NS | ND | ↑ |
| COMBO | NS | ↑ | NS | ND | ND |
| M1 macrophages | |||||
| SHP2-I | NS | ↓ | NS | ↑ | ND |
| G12C-I | NS | ↓ | NS | ND | ND |
| COMBO | NS | NS | NS | ND | ND |
| M2 macrophages | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | ↓ | NS | NS | ND | ND |
| COMBO | ↓ | NS | ↓ | ND | ND |
| Treatment . | KC GEMM . | KCP GEMM . | PDAC model . | CT26 KRAS G12D (Quintana et al., 2020) . | CT26 KRAS G12C (Canon et al., 2019) . |
|---|---|---|---|---|---|
| CD3+ T cells | |||||
| SHP2-I | ↑ | NS | ↑ | ↑ | ND |
| G12C-I | ↑ | ↑ | ↑ | ND | ↑ |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| CD19+ cells | |||||
| SHP2-I | ↑ | ↑ | NS | ND | ND |
| G12C-I | ↑ | NS | ↑ | ND | ND |
| COMBO | ↑ | NS | ↑ | ND | ND |
| CD11b+ myeloid cells | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | NS | ↓ | ND | ND |
| CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | ↑ | ND |
| G12C-I | ↑ | NS | NS | ND | ↑ |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| Activated CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | NS | ↑ | ND |
| G12C-I | NS | NS | NS | ND | ND |
| COMBO | NS | ↑ | NS | ND | ND |
| Exhausted CD8+ T cells | |||||
| SHP2-I | NS | ↑ | ↑ | NS | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | NS | ↑ | ↑ | ND | ND |
| Effector CD8+ T cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | ND | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | ↑ | ↑ | ↑ | ND | ND |
| CD4+ T cells | |||||
| SHP2-I | ↓ | ↓ | ↓ | ↑ | ND |
| G12C-I | NS | NS | NS | ND | ↑ |
| COMBO | NS | NS | ↓ | ND | ND |
| CTLA4+ CD4+ T cells | |||||
| SHP2-I | NS | ↓ | ↑ | ND | ND |
| G12C-I | NS | NS | ↑ | ND | ND |
| COMBO | ↓ | NS | ↑ | ND | ND |
| FOXP3+ CD4+ T cells | |||||
| SHP2-I | NS | NS | ↓ | ND | ND |
| G12C-I | NS | NS | NS | ND | ND |
| COMBO | ↓ | NS | ↓ | ND | ND |
| CD8+/T reg cells | |||||
| SHP2-I | ↑ | ↑ | ↑ | NS | ND |
| G12C-I | ↑ | ↑ | ↑ | ND | ND |
| COMBO | ↑ | NS | ↑ | ND | ND |
| m-MDSCs | |||||
| SHP2-I | ↑ | ↑ | ↓ | NS | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | ↑ | NS | ND | ND |
| g-MDSCs | |||||
| SHP2-I | ↑ | NS | NS | NS | ND |
| G12C-I | NS | ↑ | NS | ND | ND |
| COMBO | NS | NS | ↓ | ND | ND |
| F4/80 macrophages | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | ↑ | ↑ | NS | ND | ↑ |
| COMBO | NS | ↑ | NS | ND | ND |
| M1 macrophages | |||||
| SHP2-I | NS | ↓ | NS | ↑ | ND |
| G12C-I | NS | ↓ | NS | ND | ND |
| COMBO | NS | NS | NS | ND | ND |
| M2 macrophages | |||||
| SHP2-I | ↑ | NS | NS | ↓ | ND |
| G12C-I | ↓ | NS | NS | ND | ND |
| COMBO | ↓ | NS | ↓ | ND | ND |
Summary of changes (relative to vehicle control) in immune cell populations in the indicated models, treated as indicated. For KC and KCP GEMMs and the orthotopic PDAC model, the G12C-I was ARS and the SHP2-I was SHP099. For Quintana et al. (2020), the SHP2-I was RMC-4630, and for Canon et al. (2019), the G12C-I was AMG510. Only significant changes (P < 0.05) are shown.